Skip to Content

No difference on survival for patients with metastatic castration-resistant prostate cancer treated with apalutamide-abiraterone combination therapy

Prolonged radiologically progression-free survival did not transfer into better overall survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated with two androgen-targeted drugs instead of one.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top